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a b s t r a c t
Osteomyelitis is an inflammatory process caused by microorganisms and usually accom-
panied by bone destruction. The process may be limited to one portion of the bone or
spread to several areas such as the bone marrow, periosteum or cortex.1 It is an infection
that can occur at all ages. In children, the average age of onset is 6 years. Today, many of
these risks factors are poorly understood or inadequately addressed in healthcare. If
improperly treated, the infection can progress to chronicity, with possible recurrence
several years after the acute episode. Staphylococcus aureus is the most frequently isolated
pathogen. The treatment of acute osteomyelitis should be started at the earliest stage and
initiated in hospital with intravenous antibiotics. The antibiotic molecules used must have
good penetration in the bone and be bactericidal. The choice of the molecule for empirical
treatment must take into account the local epidemiological features and results of bacte-
riological cultures. According to epidemiological data, the prevalence of Methicillin-resis-
tant Staphylococcus aureus (MRSA) varies greatly from one country to another and from one
continent to another. Overcrowding and low social-economic background are factors
favouring the spread of MRSA in the community. Apart from ensuring early referral, the
medical community also needs to do research on the main challenges facing us in the
control of acute osteomyelitis, a disease that is especially serious in children, such as
improved diagnosis, detection of drug resistance, shortened treatment regimens and
clinical trials of new drugs.
1. Objective
Osteomyelitis is an inflammatory process caused by microor-
ganisms and usually accompanied by bone destruction. The
process may be limited to one portion of the bone or spread to
several areas such as the bonemarrow, periosteum or cortex.1
It is an infection that can occur at all ages. In children, the
average age of onset is 6 years. Today, many of these risks
factors are poorly understood or inadequately addressed in
healthcare. If improperly treated, the infection can progress to
chronicity, with possible recurrence several years after the
acute episode. Staphylococcus aureus (S. aureus) is the most
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frequently isolated pathogen. In practice, some cases are sec-
ondary to S. aureus bloodstream infections (bacteraemia)
including those due to right-sided S. aureus native valve
infective endocarditis caused by methicillin-susceptible and
methicillin-resistant strains. Vancomycin is the antibiotic
used as first choice in Methicillin-resistant S. aureus (MRSA)
infections, despite the recent emergence of some strains
resistant to this molecule. We propose in this article to take
describe the state of practice in treating this infection.
Staphylococcus aureus (S. aureus) is the most pathogenic
species of the genus Staphylococcus. It is a human
commensal and opportunistic germ that becomes a pathogen
in certain circumstances. S. aureus is found in healthy in-
dividuals in the nasal passages, throat, the gastrointestinal
tract and on the perineum. From the nasopharynx, the bac-
terium is spread onto the skin of the face and hands by
aerosols. S. aureus has pathogenicity, including potential
invasiveness and toxicity. This depends on its invasive
powers (the ability to spread in living tissue and establish one
or several seats of infection), on its toxicogenic powers (i.e. its
capacity to produce toxins) and its capacity to overcome the
host’s defencemechanisms. Toxins secreted by the bacterium
have both toxic and antigenic properties. Its pathogenicity
results from several specific secretions2:
" Deoxyribonuclease (DNase), protease;
" Toxins: enterotoxin (in some strains), staphylolysins and
leucocidins;
" Enzymes: coagulase, fibrinolysin, phosphatase, hyalur-
onidase.
2. Materials and methods
S. aureus (SA) has a great ability to give rise to antibiotic-
resistant mutants. MRSA is usually acquired in a hospital.
However in recent years we are witnessing the emergence of
MRSA in the community (CA-MRSA).3 SA strains were invari-
ably sensitive to penicillin G at the beginning of its use. Then
over the years there has been a gradual emergence of strains
resistant to penicillin and then to methicillin, through the
secretion of a specific enzyme. The advent of glycopeptides
produced but a brief respite in the fight against methicillin-
resistant SA because the 1990s saw the appearance of MRSA
strains resistant to glycopeptides. While the problem of
methicillin resistance was confined in hospitals, in the early
2000s MRSA clones were identified in the community. Today
the problem of nosocomial MRSA as well as community MRSA
has became a pandemic. According to Networks AZAY, SUC-
CEED, Ile de France, the percentage of MRSA bacteraemia in
France amounted to 25.8% in 2007. The percentage of Com-
munity MRSA (CA-MRSA) and those secreting Panton-
Valentine leukocidin (PVL) is less than 1% in a retrospective
study from 2000 to 2003. CA-MRSA causes purulent, localized
surface infections, such as boils, abscesses and infected lac-
erations occurring in patients without any risk factor for
hospital acquired strains. In the United States, the problem of
PVL-MRSA is higher reaching 57% of skin infections, 97%
of which is accounted for by USA clone. Consequently, there is
a difference between patients with nosocomial strain and
patients with a community strain (which may be more
virulent).
Antibiotics are sometimes given empirically against MRSA
which obviously do not work and additionally have the risk of
accentuation of themultidrug-resistant strains. Hence, timely
collection of sample material for laboratory testing and anal-
ysis is advised prior to treatment activity.
There are different sources of material for culture to
identify S. aureus strains, such as the nasal membrane, pus,
blood, and skin. In vitro diagnostic tests are based on the
analysis of a biological sample taken from body parts and
organs (e.g. mouth, nose and hands) using sterile swabs. A
variety of MRSA strainsmay be isolated from different clinical
infection sites: calf wound, thigh wound, abdominal pus,
lungs, vagina, eye, nose, inguinal region, axilla, umbilicus, and
nails, tongue and wound pus.4 Generally, MRSA strains are
collected from various clinical specimens from different uni-
versity hospitals or from immediate environment (e.g. air-
ways) of the patients and their relatives or visitors in diverse
hospital settings (e.g. neonatal, surgical and intensive care
units).
MRSA strains are isolated and stored at appropriate tem-
perature in suitable culturemedia and invigorated using basic
microbiological procedures. For instance, nasal samples can
be analysed for S. aureus by typical quantitative culturemeans
using a selective and differential medium. The isolation and
identification of MRSA can also be done by means of agar
diffusionmethods in solid medium or through liquid medium
procedures. In particular, chromogenic agar media test en-
ables visual characterization of MRSA colonies in a pre-
sumptive patient sample.5 Such an approach generally fits
into the group of screeningmethods that are frequently based
on microbiological growth inhibition, anti-microbial resis-
tance risk assessment or chromogenic responses allowing
identification of a suspected element of MRSA.6
Subsequently, the culture media is made using sterilized
bacterial screens for cultivation of pathogenic bacterial iso-
lates, according to guidelines of the media supplier. In prac-
tice, several techniques can be used for the identification and
detection of MRSA using a variety of laboratory diagnosis and
susceptibility testing approaches7: The laboratory diagnosis
techniques for bacterial isolation and biochemical identifi-
cation of MRSA include Tube coagulase test, Slide coagulase
test, Latex agglutination tests, DNase and heat-stable
nuclease tests, Commercial biochemical tests and Molecular
tests.
In addition, different methods have been established for
antibiotic susceptibility testing of MRSA. These methods
comprise Dilution methods, E-test method, Breakpoint
methods, Agar screening method, Disc diffusion, Latex
agglutination, Automated methods, Quenching fluorescence
method and Molecular methods. Particularly, Molecular
methods may be used for direct identification of MRSA in
blood cultures or identification of MRSA in endotracheal as-
pirates and other clinical samples.
Furthermore, detection of MRSA in screening samples is
made either with conventional methods (solid agarmedia and
enrichment) or with molecular methods. Lastly, confirmation
and quantitative analysis of MRSA is determined by the
minimum inhibitory concentration values and the bacterial
growth is characterized by the absence of the target colour-
ation to indicate drug resistance.
3. Results
In the authors’ experience, MRSA is identified using conven-
tional laboratory methods (e.g. Disc diffusion test by Kir-
byeBauer method, Oxacillin MIC, Oxacillin screen agar test,
etc.). These laboratory methods provide relevant information
for identifying bacteria (especially presence of MRSA)8 and
testing their susceptibility to antibiotics: this is called anti-
biogram analysis.9 Antibiograms are intended to help clini-
cians choose the appropriate antibiotic.
In Africa we are seeing the emergence of MRSA as illus-
trated by data from a study conducted by the Pasteur Institute
in five African countries (Cameroon, Senegal, Morocco, Niger
and Madagascar) wherein 87% of strains were resistant to
methicillin, including three major clones: ST 239/241, ST 88
and ST5. In the city of Yaounde´, Cameroon, the dominant ST
88 -SCCmec produces Hlb toxin. It is a new clone of MRSA
specific to Africa and sensitive to other antibiotics. There is a
high prevalence of PVL þMRSA in Africa: (57%), with a higher
prevalence in Cameroon: 74%. It is a routine practice to
involve a large number of family members in the care of pa-
tients in hospitals in Africa. This practice is responsible for the
distribution of hospital MRSA strains with high prevalence in
the community.
The treatment of acute osteomyelitis should be started at
the earliest stage, and initiated in hospital with intravenous
antibiotics. The antibiotic molecules used must have good
penetration into bone and be bactericidal. The choice of the
antibiotic molecule for empirical treatment must take into
account the local epidemiological features and the results of
bacteriological cultures. Germs that should be priority targets
are Methicillin Sensitive Staph. Aureus (MSSA), Kingella kingae,
Group A Streptococcus and Pneumococcus. Intravenous
therapy may be continued for 4e7 days if the response is
favourable. Intravenous antibiotic therapy is then replaced by
oral treatment for a period of 2e4 weeks.10 In general, an
initial monotherapy is sufficient, except in cases of prosthetic
infection or sepsis or shock associated toxin, where combi-
nation therapy is necessary. The molecules that may be used
are described in Table 1.
Surgical intervention may be necessary in case of purulent
collections. Sometimes several interventions are needed to
control the situation. In emergency, it is recommended to
make a simple incision with drainage of the subperiosteal
collection. Cortical trephination and intra metaphyseal
curettage are contraindicated because they may cause the
spread of infection to the metaphysis. The following clinical
signs should lead us to suspect a S. aureus producing PVL:
initial septic shock, with multifocal bone infection, necro-
tizing myositis and associated necrotizing pneumonia. Effec-
tive antibiotic treatment must be urgently instituted in order
to limit the production of toxin. It should be noted that despite
effective antibiotic therapy associated with early surgical
drainage, the evolution of PVL-SA osteomyelitis may not
improve rapidly. Complications are frequent such as sub-
periosteal abscess and muscle necrosis. Bone-related
T
a
b
le
1
e
G
iv
e
n
cu
rr
e
n
t
p
a
tt
e
rn
s
o
f
p
a
ti
e
n
t
tr
e
a
tm
e
n
t.
G
e
rm
s
In
tr
a
v
e
n
o
u
s
tr
e
a
tm
e
n
t
(I
V
tr
e
a
tm
e
n
t)
O
ra
l
re
la
y
F
ir
st
ch
o
ic
e
A
lt
e
rn
a
ti
v
e
s
F
ir
st
ch
o
ic
e
A
lt
e
rn
a
ti
v
e
s
S
A
M
S
C
lo
x
a
ci
ll
in
5
0
m
g
/k
g
/6
h
A
m
o
x
ic
il
li
n
/c
la
v
u
la
n
ic
a
ci
d
3
5
m
g
/k
g
/
6
h
o
r
C
li
n
d
a
m
y
ci
n
1
0
m
g
/k
g
/6
h
A
m
o
x
ic
il
li
n
/c
la
v
u
la
n
ic
a
ci
d
8
0
m
g
/k
g
/
2
4
h
C
li
n
d
a
m
y
ci
n
1
5
m
g
/k
g
/8
h
o
r
C
o
tr
im
o
x
a
z
o
le
1
5
e
2
0
m
g
/k
g
/8
h
S
A
R
M
V
a
n
co
m
y
ci
n
1
5
m
g
/k
g
/6
h
,
o
r
IV
co
n
ti
n
u
o
u
s
þ
R
if
a
m
p
ic
in
1
0
m
g
/k
g
/
1
2
h
C
li
n
d
a
m
y
ci
n
1
0
m
g
/k
g
/6
h
C
li
n
d
a
m
y
ci
n
1
5
m
g
/k
g
/8
h
R
if
a
m
p
ic
in
1
0
m
g
/k
g
/
1
2
h
þ
C
o
tr
im
o
x
a
z
o
le
1
5
w
it
h
2
0
m
g
/
k
g
/8
h
o
r
þ
F
u
si
d
ic
a
ci
d
1
5
w
it
h
2
0
m
g
/
k
g
/8
h
S
A
R
M
e
P
V
L
C
li
n
d
a
m
y
ci
n
1
0
m
g
/k
g
/
6
h
þ
G
e
n
ta
m
ic
in
5
e
7
,
5
m
g
/k
g
/2
4
h
R
if
a
m
p
ic
in
1
0
m
g
/k
g
/
1
2
h
þ
G
e
n
ta
m
ic
in
5
e
7
,
5
m
g
/k
g
/2
4
h
sequelae may ultimately require reconstructive surgeries at a
later date.11
4. Discussion
According to epidemiological data, the prevalence of MRSA
varies greatly from one country to another and from one
continent to another. Overcrowding and poor socio-economic
status are factors favouring the spread of MRSA in the com-
munity.12 Pathogenic strains also differ according to the
environment. Correct identification of the strain is very
important for deciding the choice of antibiotic treatment. The
role of the laboratory is important here to determine the types
of strains involved in infections, as well as to determine the
resistance rate of MRSA to antibiotics or other anti-microbial
agents.13 Delay in laboratory identification should not how-
ever delay the initiation of empirical antibiotic treatment.
Vancomycin remains the first choice in the treatment of acute
MRSA osteomyelitis in children. Its use as monotherapy is not
recommended. The choice of antibiotics should also take into
account the severity of the clinical picture and the epidemi-
ological situation. If the clinical picture is suggestive of serious
sepsis, fasciitis or necrotizing myositis and associated pneu-
monia, then one must suspect an MRSA-PVL. In this case it is
recommended to use a molecule which can reduce toxin
production such as clindamycin or rifamycin, and start with
combination treatment rather than monotherapy. Elements
used to monitor the response to treatment (which is impor-
tant to decide the duration of treatment) in recent studies
were the reduction of certain clinical signs, decreased CRP
below 20 mg/l, and the decrease in ESR. The treatment con-
sists of initial intravenous antibiotic for 4e7 days, followed by
switch to oral if there is a favourable outcome, for a total
duration of treatment from 2 to 4 weeks. This scheme has the
advantage of reducing the length of hospitalization, and
therefore the cost of treatment and the risk of nosocomial
infections. It is necessary to perform randomized studies to
codify the duration of treatment of MRSA-PVL osteomyelitis
and improve medical practice.
5. Conclusion
Apart from ensuring early referral, the medical community
also needs to do research on the main challenges facing us in
the control of acute osteomyelitis,14 a disease that is especially
serious in children, such as improved diagnosis, detection of
drug resistance, shortened treatment regimens and clinical
trials of new drugs. Principally, knowledge about MRSA
propagating clones is essential to implement any policies to
monitor the spread of MRSA either within hospitals or in
community.15 Particular anti-staphylococcal antibiotics
should be considered in experienced-based treatment of
sepsis among them.16
Ecological approaches provide interesting information on
alternative methods to prevent infections with a non-antibi-
otic strategy.17 An example of such alternative methods is the
use of probiotics that are described as products which include
viable non-pathogenic microorganisms capable to give health
advantages to the host.18 For instance, treatment with selects
probiotic strains is promising since lactic acid bacteria strains
(cultivated on natural media, such as milk or soya) express an
anti-MRSA activity.19 Finally, applicable prevention and
infection control practices (e.g. Intravenous immunoglobulin,
anti-staphylococcal monoclonal antibodies, granulocyte/
granulocyte-macrophage colony-stimulating factors and
judicious use of antibiotics) are essential for advances in the
treatment of paediatric infectious diseases.20
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